<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01738087</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-1205-PR-0087</org_study_id>
    <secondary_id>2012-002370-30</secondary_id>
    <nct_id>NCT01738087</nct_id>
  </id_info>
  <brief_title>Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder</brief_title>
  <official_title>A Phase II, Monocentric, Open, Randomized, 6-way Cross-over Clinical Pharmacology Study to Evaluate the Lung Bioavailability of BDP/B17MP and Formoterol and the Total Systemic Exposure Across Two Different Strengths of CHF 1535 NEXThaler Dry Powder Inhaler (Fixed Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate 100/6 mcg and 200 mcg) Administered With and Without Activated Charcoal in Adult Asthmatic Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to assess the dose proportional total systemic exposure (when the
      administration is without the activated charcoal) to B17MP (active metabolite of BDP) and its
      lung bioavailability (when the administration is with the activated charcoal) after single
      inhalation of CHF 1535 NEXThaler DPI at two dose strengths.

      At the same time, the study will assess if the lung deposition and the total systemic
      exposure to Formoterol is affected by increasing doses of BDP.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Formoterol AUC0-t and B17MP AUC0-t</measure>
    <time_frame>from predose until 12 hr post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>BDP pharmacokinetic (PK) parameters</measure>
    <time_frame>from predose until 12 hr post dose</time_frame>
    <description>The following parameters will be evaluated: AUC0-t, AUC0-12h, AUC0-inf, Cmax, tmax, t1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other PK parameter of B17MP and formoterol</measure>
    <time_frame>from predose until 12 hours postdose</time_frame>
    <description>the following pharmacokinetic parameters will be evaluated: AUC0-12, AUCinf, Cmax, tmax, t1/2</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma glucose</measure>
    <time_frame>from predose until 12 hours postdose</time_frame>
    <description>the following parameters will be evaluated: AUC0-4h, AUC0-12h, Cmax and tmax</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate (HR)</measure>
    <time_frame>from predose until 12 hours postdose</time_frame>
    <description>the following parameters will be evaluated: HR AUC0-12/12h</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma cortisol</measure>
    <time_frame>from predose until 24 hours postdose</time_frame>
    <description>the following parameters will be evaluated: AUC0-24, Cmin and tmin</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma potassium</measure>
    <time_frame>from predose until 12 hours postdose</time_frame>
    <description>the following parameters will be evaluated: AUC0-4h, AUC0-12h, Cmin ad tmin</description>
  </other_outcome>
  <other_outcome>
    <measure>Systolic and Diastolic Blood Pressure (SBP and DBP)</measure>
    <time_frame>from predose until 12 hours postdose</time_frame>
    <description>the following parameters will be evaluated: SBP AUC0-12/12h and DBP AUC0-12/12h</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Asthmatic</condition>
  <arm_group>
    <arm_group_label>NEXThaler 100/6 mcg DPI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose (4 inhalations)of NEXThaler 100/6 mcg DPI: total dose 400/24 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NEXThaler 200/6 mcg DPI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose (4 inhalations)of NEXThaler 200/6 mcg DPI: total dose: 800/24 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NEXThaler placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose (4 inhalations)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NEXThaler 100/6 mcg plus CB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose (4 inhalations) NEXThaler 100/6 mcg administered with activated charcoal (Charcoal Block): total dose 400/24 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NEXThaler 200/6 mcg plus CB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose (4 inhalations) NEXThaler 200/6 mcg administered with activated charcoal (Charcoal Block): total dose 800/24 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flixotide Accuhaler 500 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose (2 inhalations) of fluticasone propionate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NEXThaler 100/6 mcg DPI</intervention_name>
    <arm_group_label>NEXThaler 100/6 mcg DPI</arm_group_label>
    <arm_group_label>NEXThaler 100/6 mcg plus CB</arm_group_label>
    <other_name>Fixed combination of BDP plus formoterol fumarate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flixotide Accuhaler 500 mcg</intervention_name>
    <description>Active comparator</description>
    <arm_group_label>Flixotide Accuhaler 500 mcg</arm_group_label>
    <other_name>Fluticasone Propionate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NEXThaler 200/6 mcg DPI</intervention_name>
    <arm_group_label>NEXThaler 200/6 mcg DPI</arm_group_label>
    <arm_group_label>NEXThaler 200/6 mcg plus CB</arm_group_label>
    <other_name>Fixed combination of BDP plus formoterol fumarate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NEXThaler placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>NEXThaler placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of asthma as defined by Global Initiative for Asthma (GINA) 2011

          -  Asthmatic patients already treated with low daily doses of Inhaled Corticosteroids
             (ICS) (eg budesonide or equivalent lower than 400 mcg/day) or low dose of ICS/Long
             Acting Beta2 Agonists (LABA) fixed combinations.

          -  Patients with Forced Expiratory Volume in 1 sec (FEV1) &gt;= 70 % of predicted values

          -  Non or ex-smokers

          -  Body Mass Index (BMI) &gt;= 18.5 and &lt;= 32 kg/m2

        Exclusion Criteria:

          -  Pregnant or lactating women unless using acceptable methods of contraception

          -  Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)

          -  History of near fatal asthma

          -  Patients with abnormal QTcF at screening Visit

          -  Hospitalization due to asthma exacerbation within 4 weeks prior to the screening visit
             or during the run-in period.

          -  Lower respiratory tract infection within 4 weeks prior to the screening visit or
             during the run-in period.

          -  History of drug addiction or excessive use of alcohol ;

          -  Diagnosis of restrictive lung disease.

          -  Patients treated with oral or parenteral corticosteroids in the previous 2 months
             before the screening visit (3 months for parenteral depot corticosteroids)

          -  Significant medical history or any laboratory abnormality indicative of a significant
             underlying condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Medicine Evaluation Unit</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002370-30</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2012</study_first_submitted>
  <study_first_submitted_qc>November 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2012</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>patients</keyword>
  <keyword>Adult</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Charcoal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

